What is the official website of Laboratoire Modilac – Groupe Savencia ?

The official website of Laboratoire Modilac – Groupe Savencia is http://www.modilac.fr.

What is Laboratoire Modilac – Groupe Savencia's cybersecurity risk score?

Laboratoire Modilac – Groupe Savencia has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Laboratoire Modilac – Groupe Savencia experienced?

According to Rankiteo, Laboratoire Modilac – Groupe Savencia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Laboratoire Modilac – Groupe Savencia been affected by any supply chain cyber incidents ?

According to Rankiteo, Laboratoire Modilac – Groupe Savencia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Laboratoire Modilac – Groupe Savencia have SOC 2 Type 1 certification ?

According to Rankiteo, Laboratoire Modilac – Groupe Savencia is not certified under SOC 2 Type 1.

Does Laboratoire Modilac – Groupe Savencia have SOC 2 Type 2 certification ?

According to Rankiteo, Laboratoire Modilac – Groupe Savencia does not hold a SOC 2 Type 2 certification.

Does Laboratoire Modilac – Groupe Savencia comply with GDPR ?

According to Rankiteo, Laboratoire Modilac – Groupe Savencia is not listed as GDPR compliant.

Does Laboratoire Modilac – Groupe Savencia have PCI DSS certification ?

According to Rankiteo, Laboratoire Modilac – Groupe Savencia does not currently maintain PCI DSS compliance.

Does Laboratoire Modilac – Groupe Savencia comply with HIPAA ?

According to Rankiteo, Laboratoire Modilac – Groupe Savencia is not compliant with HIPAA regulations.

Does Laboratoire Modilac – Groupe Savencia have ISO 27001 certification ?

According to Rankiteo,Laboratoire Modilac – Groupe Savencia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Laboratoire Modilac – Groupe Savencia operate in ?

Laboratoire Modilac – Groupe Savencia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Laboratoire Modilac – Groupe Savencia have ?

Laboratoire Modilac – Groupe Savencia employs approximately 117 people worldwide.

Does Laboratoire Modilac – Groupe Savencia own any subsidiaries ?

Laboratoire Modilac – Groupe Savencia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Laboratoire Modilac – Groupe Savencia have ?

Laboratoire Modilac – Groupe Savencia's official LinkedIn profile has approximately 4,296 followers.

What is the NAICS classification code for Laboratoire Modilac – Groupe Savencia ?

Laboratoire Modilac – Groupe Savencia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Laboratoire Modilac – Groupe Savencia have a Crunchbase profile ?

No, Laboratoire Modilac – Groupe Savencia does not have a profile on Crunchbase.

Does Laboratoire Modilac – Groupe Savencia have a LinkedIn profile ?

Yes, Laboratoire Modilac – Groupe Savencia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/sodilac.

How many cybersecurity incidents has Laboratoire Modilac – Groupe Savencia experienced ?

As of June 15, 2026, Rankiteo reports that Laboratoire Modilac – Groupe Savencia has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Laboratoire Modilac – Groupe Savencia have ?

Laboratoire Modilac – Groupe Savencia has an estimated 5,690 peer or competitor companies worldwide.

What types of cybersecurity incidents has Laboratoire Modilac – Groupe Savencia faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

LMGS

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Laboratoire Modilac – Groupe Savencia Vendor Cyber Rating & Cyber Score

modilac.fr

Add Your Compliance Badge

Laboratoire Modilac est spécialisé en nutrition infantile. La marque Laboratoire Modilac est commercialisée en pharmacie et en GMS. Depuis plus de 40 ans, nous contribuons activement à l’évolution de la nutrition infantile et au développement de formules très innovantes de haute qualité en gardant toujours pour référence la composition du lait maternel. Avis Important : Le lait maternel est l'aliment idéal naturel du nourrisson et de l'enfant en bas âge.

LMGS A.I CyberSecurity Scoring

Scoring History

LMGS

Laboratoire Modilac – Groupe Savencia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Laboratoire Modilac...

Cyber Attack

10/2023

VAL939072525

Laboratoire Modilac...

Breach

9/2021

VAL723072525

Loading…

A.I.

LMGS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for LMGS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Laboratoire Modilac – Groupe Savencia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Laboratoire Modilac – Groupe Savencia in 2026.

Incident Types LMGS vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Laboratoire Modilac – Groupe Savencia in 2026.

Incident History - LMGS (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Laboratoire Modilac – Groupe Savencia Subsidiaries

LMGS

Pharmaceutical Manufacturing

Website: http://www.modilac.fr

Company Size: 51-200 employees

SAVENCIAFood and Beverage Manufacturing

Cheese Lover Shop - Groupe SavenciaFood and Beverage Retail

VALRHONAFood and Beverage Manufacturing

Fonds Solidaire ValrhonaOrganisations à but non lucratif

Polenghi Indústrias Alimentícias Ltda.Food and Beverage Services

Bordeau Chesnel - Coraya - Saint Agaûne - Groupe SavenciaFood and Beverage Manufacturing

De Neuville - Groupe SavenciaRetail

Mantequerías Arias - Groupe SavenciaFood and Beverage Manufacturing

Weiss - Chocolaterie françaiseFood and Beverage Manufacturing

REVILLON CHOCOLATIER - Groupe SavenciaFood and Beverage Manufacturing

SAVENCIA Fromage & Dairy Deutschland - Groupe SavenciaFood and Beverage Manufacturing

Compagnie des Fromages & RichesMonts - Groupe SAVENCIAFood and Beverage Manufacturing

Villars Maître Chocolatier Groupe SavenciaFood Production

La Maison du ChocolatRetail

Savencia Fromage & Dairy BrasilFood and Beverage Manufacturing

Savencia Fromage & Dairy Benelux - Groupe SavenciaFood Production

República del CacaoFood and Beverage Manufacturing

Armor Dairy - Groupe SavenciaFood and Beverage Manufacturing

Elvor - Groupe SavenciaFarming

CHEESE INGREDIENTS - Groupe SavenciaFabrication de produits alimentaires et boissons

ARMOR PROTEINES - groupe SavenciaFood Production

AFP advanced food products llc, Groupe SavenciaFood & Beverages

ARMOR PHARMAPharmaceutical Manufacturing

CormanFood and Beverage Manufacturing

Elle & Vire - Groupe SavenciaFood and Beverage Manufacturing

Loading…

Laboratoire Modilac – Groupe Savencia Similar Companies

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Loading…

NEWS

Laboratoire Modilac – Groupe Savencia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12191

SUMMARY

A vulnerability was found in Comma AI Openpilot 0.11. This issue affects the function pickle.load/pickle.loads of the file selfdrive/modeld/modeld.py of the component Pickle Module. The manipulation results in deserialization. The attack is only possible with local access. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 7.8)

cvss2

Base Score: 6.8

Complexity: LOW

AV:L/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-12190

SUMMARY

A vulnerability has been found in Genspark AI Workspace App 2.8.4 on Android. This vulnerability affects unknown code of the component ai.mainfunc.genspark. The manipulation leads to improper authorization in handler for custom url scheme. The attack can only be performed from a local environment. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-12189

SUMMARY

A flaw has been found in Moovit Bus & Public Transit App 1.18 on Android. This affects an unknown part of the component com.tranzmate. Executing a manipulation can lead to improper authorization in handler for custom url scheme. The attack can only be executed locally. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-12188

SUMMARY

A vulnerability was detected in Grit42 Grit up to 0.11.0. Affected by this issue is some unknown functionality of the file modules/core/backend/app/controllers/concerns/grit/core/grit_entity_controller.rb of the component GritEntityController. Performing a manipulation results in sql injection. The attack may be initiated remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-12187

SUMMARY

A security vulnerability has been detected in GL.iNet GL-MT3000 up to 4.4.5. Affected by this vulnerability is an unknown functionality of the file /usr/bin/one_click_upgrade of the component Online Firmware Upgrade Handler. Such manipulation leads to command injection. The attack can be launched remotely. The exploit has been disclosed publicly and may be used. Upgrading to version 4.7 addresses this issue. Upgrading the affected component is advised. The vendor was contacted early, responded in a very professional manner and quickly released a fixed version of the affected product.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…